595526 Disclosed is the use of an aqueous pharmaceutical composition comprising a VLA-4 binding antibody at a concentration of about 120 mg/ml to about 190 mg/ml, a sodium phosphate buffer at a concentration of about 5 mM to about 15 mM, sodium chloride at a concentration of about 130 mM to about 150 m 5 M and polysorbate at an amount of about 0.02% to about 0.08% (w/v), wherein the pH of the composition is pH 6+-0.5 in the manufacture of a medicament for the treatment of an inflammatory, immune, or autoimmune disorder.
